← United States · Coverage record
US · SEC FORM 4
Ventyx Biosciences, Inc.
VTYX · — · CIK 0001851194 · Healthcare
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-12-23 · Gujrathi Sheila.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2024-12-23 | Gujrathi Sheila | Purchase (P) | Common Stock | 130,000 | USD 2.31 | USD 300,300 | SEC filing ↗ |
| 2024-11-25 | Mohan Raju | Purchase (P) | Common Stock | 261,752 | USD 2.01 | USD 526,122 | SEC filing ↗ |
| 2024-11-22 | Mohan Raju | Purchase (P) | Common Stock | 238,248 | USD 1.83 | USD 435,994 | SEC filing ↗ |
| 2021-10-25 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund III LP | Purchase (P) | Common Stock | 625,000 | USD 16.00 | USD 10,000,000 | SEC filing ↗ |
| 2021-10-25 | Royston Aaron | Purchase (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC filing ↗ |
| 2021-10-25 | Adelman Robert J; GOODMAN COREY S; VENBIO GLOBAL STRATEGIC GP III, L.P.; VENBIO GLOBAL STRATEGIC GP III, LTD; venBio Global Strategic Fund III, L.P. | Purchase (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC filing ↗ |
Form 4 evidence
13 transaction lines in the latest 365-day window; 285 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Subramaniam Somu | D (D) | Common Stock | 3,337,495 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | Nuss John | D (D) | Common Stock | 489,481 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | Mohan Raju | D (D) | Common Stock | 2,372,863 | USD — | USD — | SEC filing ↗ |
Show recent Form 4 evidence (13 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Subramaniam Somu | D (D) | Common Stock | 3,337,495 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | Nuss John | D (D) | Common Stock | 489,481 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | Mohan Raju | D (D) | Common Stock | 2,372,863 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | Gonzales Roy | D (D) | Common Stock | 5,313 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | GUJRATHI SHEILA | D (D) | Common Stock | 130,000 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | Forman Mark S | D (D) | Common Stock | 6,000 | USD — | USD — | SEC filing ↗ |
| 2026-02-27 | Subramaniam Somu | J (J) | Common Stock | 694,718 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-18 | Nuss John | Sale (S) | Common Stock | 12,675 | USD 7.72 | USD 97,851 | SEC filing ↗ |
| 2025-12-18 | Mohan Raju | Sale (S) | Common Stock | 47,345 | USD 7.72 | USD 365,503 | SEC filing ↗ |
| 2025-12-17 | Nuss John | Option exercise / conversion (M) | Common Stock | 34,930 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-17 | Mohan Raju | Option exercise / conversion (M) | Common Stock | 116,668 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-11-17 | Gonzales Roy | Award / grant (A) | Common Stock | 1,767 | USD 1.03 | USD 1,820 | SEC filing ↗ |
| 2025-11-17 | Forman Mark S | Award / grant (A) | Common Stock | 3,000 | USD 1.03 | USD 3,090 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | VTYX |
| CIK | 0001851194 |
| Sector | Healthcare |
| Industry | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | — |
Data coverage
| Local Form 4 history | 285 transaction lines from 2021-10-25 to 2026-03-04 6 P purchase lines · 178 S sale lines · 101 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.